Review ArticleConsideration Regarding the Analysis of Randomized Controlled Trials in the Era of Evidence-based MedicineEnnezat, Pierre V. MD*; Alavi, Zarrin MSc†; Le Jemtel, Thierry H. MD‡; Hansen, Morten R. MD, PhD§,¶ Author Information *Department of Cardiology, Centre Hospitalier Universitaire Henri Mondor, Créteil, France; †INSERM, CIC 1412, Centre Hospitalier Universitaire de Brest, Brest, France; ‡Tulane University Heart and Vascular Institute, New Orleans, LA; §Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark; and ¶Department of Clinical Biochemistry and Pharmacology Odense University Hospital, Odense, Denmark. Correspondence: Pierre V. Ennezat, MD, Cardiology Department, CHU Henri-Mondor, Créteil, France (e-mail: [email protected] or [email protected]). The authors report no conflicts of interest. Journal of Cardiovascular Pharmacology: May 2022 - Volume 79 - Issue 5 - p 605-619 doi: 10.1097/FJC.0000000000001215 Buy Metrics Abstract Analysis of randomized controlled trials (RCTs) is the cornerstone of evidence-based medicine, therapeutic guidelines and ultimately daily practice. However, 2 issues contribute to cloud the analysis of RCTs. Industry-sponsored RCTs aim at capturing as large indications as possible and clinicians rely excessively on P value statistical significance for the evaluation of the findings. To be most valuable to practitioners, analysis of RCTs needs to provide absolute risk reduction, number of patients needed to treat, fragility index along with the estimation of lost to follow-up patients, and outcome postponement (gain in survival time). We analyzed few major cardiovascular RCTs and assessed the robustness of their findings. Our suggested analytic parameters may be further used in future systematic reviews and meta-analyses. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.